Caricamento...
Regression of brain metastases from breast cancer with eribulin: a case report
BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3878316/ https://ncbi.nlm.nih.gov/pubmed/24350786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-541 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|